Zoetis Inc. (NYSE:ZTS) Stock Holdings Lessened by OLD National Bancorp IN

OLD National Bancorp IN lowered its stake in Zoetis Inc. (NYSE:ZTS) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,920 shares of the company’s stock after selling 649 shares during the period. OLD National Bancorp IN’s holdings in Zoetis were worth $576,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in ZTS. International Assets Investment Management LLC raised its stake in Zoetis by 25.1% during the 3rd quarter. International Assets Investment Management LLC now owns 1,726 shares of the company’s stock valued at $302,000 after purchasing an additional 346 shares during the period. Capital Investment Advisors LLC increased its stake in shares of Zoetis by 38.1% in the third quarter. Capital Investment Advisors LLC now owns 2,263 shares of the company’s stock worth $394,000 after acquiring an additional 624 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of Zoetis in the third quarter worth $214,000. Proficio Capital Partners LLC increased its stake in shares of Zoetis by 3.2% in the third quarter. Proficio Capital Partners LLC now owns 2,544 shares of the company’s stock worth $443,000 after acquiring an additional 79 shares during the last quarter. Finally, RDA Financial Network increased its stake in shares of Zoetis by 39.2% in the third quarter. RDA Financial Network now owns 2,200 shares of the company’s stock worth $383,000 after acquiring an additional 619 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS opened at $150.89 on Thursday. The stock’s 50 day simple moving average is $173.11 and its 200-day simple moving average is $179.58. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a market cap of $69.01 billion, a PE ratio of 29.76, a P/E/G ratio of 2.29 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the company earned $1.15 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis. Sell-side analysts forecast that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 2,209 shares of company stock valued at $371,293. 0.12% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. The Goldman Sachs Group upped their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, Stifel Nicolaus decreased their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $218.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.